ABSTRACT
O linfoma canino resulta na proliferação descontrolada dos linfócitos malignos originados pelas células linforreticulares, acometendo principalmente os órgãos linfóides que são os linfonodos, fígado, medula óssea e baço. É considerado a neoplasia linfoproliferativa mais comum, a qual pode ser classificada de acordo com a sua localização anatômica nas formas: multicêntrico, alimentar, cutâneo, tímico e extranodal. O objetivo desse trabalho foi relatar os aspectos clínicos do linfoma em um cão portador da Leishmaniose visceral canina, bem como ressaltar a importância dos exames complementares para a obtenção de um diagnóstico preciso em casos de co-morbidade. Foi atendido no Hospital Veterinário Metropolitano de Caucaia (HVM), um canino da raça Doberman, macho, 5 anos de idade, pesando 30 quilos, apresentando edemaciação no membro anterior esquerdo, mucosas hipocoradas, halitose, desidratação, febre, descamação e lesão na pele, onicogrifose, anorexia, nódulos subcutâneo e linfonodos palpáveis, sendo que o linfonodo axilar esquerdo estava acentuadamente aumentado. De acordo com a anamnese e exame físico, foram solicitados os exames hematológicos, bioquímicos (análises renal e hepática), sorologia para Calazar, radiografia de tórax e citologia do linfonodo. O resultado da citologia indicou um quadro neoplásico sugestivo de linfoma e a sorologia foi reagente para leishmaniose. O paciente foi encaminhado para o oncologista com o intuito de o especialista instituir a melhor forma terapêutica para o linfoma, dando assim o prognóstico adequado, porém o animal veio a óbito devido sua progressiva condição clínica antes de iniciar o tratamento. Conclui-se que os sinais clínicos juntamente com os exames complementares são importantes na obtenção do diagnóstico para o linfoma e leishmaniose, partindo do princípio que essas enfermidades podem acometer o animal de forma isolada ou conjunta.(AU)
Canine lymphoma results in the uncontrolled proliferation of malignant lymphocytes originating from lymphoreticular cells, mainly affecting lymphoid organs such as lymph nodes, liver, bone marrow and spleen. It is considered the most common lymphoproliferative neoplasia, which can be classified according to its anatomical location in the forms: multicentric, alimentary, cutaneous, thymic and extranodal. The objective of this study was to report the clinical aspects of lymphoma in a dog with canine visceral leishmaniasis, as well as to emphasize the importance of complementary tests to obtain an accurate diagnosis in cases of comorbidities. A 5-year-old male Doberman dog, weighing 30 kg, was attended at the Metropolitan Veterinary Hospital of Caucaia (HVM), presenting with edema in the left anterior limb, hypocorous mucosae, halitosis, dehydration, fever, peeling and skin lesion, onychogrifose, anorexia, subcutaneous nodules and palpable lymph nodes, and the left axillary lymph node was markedly enlarged. According to the anamnesis and physical examination, hematological, biochemical (renal and hepatic reviews) tests, serology for Calazar, chest X-ray and lymph node cytology were requested. The cytology result indicated a neoplastic picture suggestive of lymphoma and the serology was reactive for leishmaniasis. The patient was referred to the oncologist in order to establish the best therapeutic form for the lymphoma, thus giving the appropriate prognosis, but the animal died due to its progressive clinical condition before starting the treatment. It is concluded that the clinical signs together with the complementary exams are important in obtaining the diagnosis for lymphoma and leishmaniasis, assuming that these diseases can affect the animal in isolation or in a joint manner.(AU)
Subject(s)
Animals , Male , Dogs , Leishmaniasis, Visceral/diagnosis , Leishmaniasis, Visceral/veterinary , Leishmaniasis, Visceral/complications , Lymphoma/complications , Lymphoma/diagnosis , Lymphoma/veterinary , ComorbidityABSTRACT
O linfoma canino resulta na proliferação descontrolada dos linfócitos malignos originados pelas células linforreticulares, acometendo principalmente os órgãos linfóides que são os linfonodos, fígado, medula óssea e baço. É considerado a neoplasia linfoproliferativa mais comum, a qual pode ser classificada de acordo com a sua localização anatômica nas formas: multicêntrico, alimentar, cutâneo, tímico e extranodal. O objetivo desse trabalho foi relatar os aspectos clínicos do linfoma em um cão portador da Leishmaniose visceral canina, bem como ressaltar a importância dos exames complementares para a obtenção de um diagnóstico preciso em casos de co-morbidade. Foi atendido no Hospital Veterinário Metropolitano de Caucaia (HVM), um canino da raça Doberman, macho, 5 anos de idade, pesando 30 quilos, apresentando edemaciação no membro anterior esquerdo, mucosas hipocoradas, halitose, desidratação, febre, descamação e lesão na pele, onicogrifose, anorexia, nódulos subcutâneo e linfonodos palpáveis, sendo que o linfonodo axilar esquerdo estava acentuadamente aumentado. De acordo com a anamnese e exame físico, foram solicitados os exames hematológicos, bioquímicos (análises renal e hepática), sorologia para Calazar, radiografia de tórax e citologia do linfonodo. O resultado da citologia indicou um quadro neoplásico sugestivo de linfoma e a sorologia foi reagente para leishmaniose. O paciente foi encaminhado para o oncologista com o intuito de o especialista instituir a melhor forma terapêutica para o linfoma, dando assim o prognóstico adequado, porém o animal veio a óbito devido sua progressiva condição clínica antes de iniciar o tratamento. Conclui-se que os sinais clínicos juntamente com os exames complementares são importantes na obtenção do diagnóstico para o linfoma e leishmaniose, partindo do princípio que essas enfermidades podem acometer o animal de forma isolada ou conjunta.
Canine lymphoma results in the uncontrolled proliferation of malignant lymphocytes originating from lymphoreticular cells, mainly affecting lymphoid organs such as lymph nodes, liver, bone marrow and spleen. It is considered the most common lymphoproliferative neoplasia, which can be classified according to its anatomical location in the forms: multicentric, alimentary, cutaneous, thymic and extranodal. The objective of this study was to report the clinical aspects of lymphoma in a dog with canine visceral leishmaniasis, as well as to emphasize the importance of complementary tests to obtain an accurate diagnosis in cases of comorbidities. A 5-year-old male Doberman dog, weighing 30 kg, was attended at the Metropolitan Veterinary Hospital of Caucaia (HVM), presenting with edema in the left anterior limb, hypocorous mucosae, halitosis, dehydration, fever, peeling and skin lesion, onychogrifose, anorexia, subcutaneous nodules and palpable lymph nodes, and the left axillary lymph node was markedly enlarged. According to the anamnesis and physical examination, hematological, biochemical (renal and hepatic reviews) tests, serology for Calazar, chest X-ray and lymph node cytology were requested. The cytology result indicated a neoplastic picture suggestive of lymphoma and the serology was reactive for leishmaniasis. The patient was referred to the oncologist in order to establish the best therapeutic form for the lymphoma, thus giving the appropriate prognosis, but the animal died due to its progressive clinical condition before starting the treatment. It is concluded that the clinical signs together with the complementary exams are important in obtaining the diagnosis for lymphoma and leishmaniasis, assuming that these diseases can affect the animal in isolation or in a joint manner.
Subject(s)
Male , Animals , Dogs , Comorbidity , Leishmaniasis, Visceral/complications , Leishmaniasis, Visceral/diagnosis , Leishmaniasis, Visceral/veterinary , Lymphoma/complications , Lymphoma/diagnosis , Lymphoma/veterinaryABSTRACT
A lipid nanoemulsion (LDE) resembling low-density lipoprotein can target malignant tumours. In in vivo and clinical studies, association of chemotherapeutic agents to LDE decreased their toxicity and increased pharmacological action. Here, safety of LDE as carmustine carrier (50 mg m(-2) , intravenous) combined with vincristine and prednisone for the treatment of dogs with lymphoma was tested and compared with commercial carmustine with vincristine and prednisone. In five dogs from LDE-carmustine and six from commercial carmustine, complete remission was achieved (P > 0.05). Partial remission occurred in two dogs from each group. In both groups, the median progression-free intervals (119 and 199 days) and overall survival times (207 and 247 days) were equal. Neutropenia was observed in both groups, but no other major toxicities occurred. Therefore, no difference was observed between the treatments. LDE-carmustine was shown to be safe and effective in a drug combination protocol, which encourages larger studies to investigate the use of this novel formulation to treat canine lymphomas.